These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9147856)

  • 1. [Effect of clodronate in patients with multiple myeloma. Evaluation of specific markers of bone resorption].
    Slabý J; Spicka I; Hulejová H; Spacek P; Cieslar P; Klener P
    Cas Lek Cesk; 1997 Jan; 136(2):57-60. PubMed ID: 9147856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring markers of bone turnover in multiple myeloma].
    Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
    Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects.
    Ohishi T; Takahashi M; Kawana K; Aoshima H; Hoshino H; Horiuchi K; Kushida K; Inoue T
    Clin Invest Med; 1993 Oct; 16(5):319-25. PubMed ID: 8261685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of clodronate on bone density in patients with multiple myeloma--a 2-year follow-up of therapeutic effects].
    Adam Z; Prokes B; Znojĭl V; Vorlícek J; Hejlová N; Hájek D; Krejcí M
    Vnitr Lek; 1996 Jun; 42(6):379-85. PubMed ID: 8928406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.
    Body JJ; Delmas PD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):471-5. PubMed ID: 1740478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increased bone density in patients with multiple myeloma treated with clodronate].
    Adam Z; Prokes B; Hájek D; Vorlícek J; Tomíska M; Hájek J; Penka M; Mayer J; Hejlová N
    Vnitr Lek; 1994 Nov; 40(11):726-9. PubMed ID: 7810097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of bone markers in dairy cows with parturient paresis].
    Liesegang A; Eicher R; Kraenzlin M; Rüsch P; Wanner M; Riond JL
    Schweiz Arch Tierheilkd; 1998; 140(10):405-11. PubMed ID: 9803160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases].
    Takeuchi S; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of urinary pyridinium crosslink excretion as a marker of bone resorption in the rat.
    Egger CD; Mühlbauer RC; Felix R; Delmas PD; Marks SC; Fleisch H
    J Bone Miner Res; 1994 Aug; 9(8):1211-9. PubMed ID: 7976504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures.
    Mitra D; Elvins DM; Collins AJ
    J Rheumatol; 1999 Oct; 26(10):2201-4. PubMed ID: 10529140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
    Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
    Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
    Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
    Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal study of bone-related biochemical changes at the menopause.
    Nordin BE; WIshart JM; Clifton PM; McArthur R; Scopacasa F; Need AG; Morris HA; O'Loughlin PD; Horowitz M
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):123-30. PubMed ID: 15212654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
    Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
    J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.